Table 1. Clinical response of brilacidin (PMX-30063) and daptomycin in acute bacterial skin and skin structure infections: a Phase II study.

Clinical response	Low dose	Medium dose	High dose	Daptomycin
	N = 52	N = 54	N = 54	N = 55
Day 3	94.4%	90.7%	81.5%	90.6%
Day 7	87.0%	92.6%	83.3%	96.2%
Sustained response
Day 10	90.2%	91.8%	95.5%	97.9%
Day 28	95.7%	89.6%	95.6%	98.0%